[nanoPost] novel, nanotechnology-based therapeutics

NanoBiology Platform

An example of the company’s NanoBiology focus is its first technological application. Licensed exclusively from the Massachusetts Institute of Technology, the company uses its proprietary Nanocell technology to develop multi-compartmental nanoparticle-based therapeutics in which two or more drugs with varied release times are packaged within the nanocapsule, allowing for sequential delivery of the drugs, optimizing the location, time and combinatorial effect of two therapies while minimizing toxicities.

Researchers designed a nanocapsule that preferentially distributed to a cancerous tumor; the nanocapsule then released a vascular targeting drug, leading to the collapse of the vascular network and trapping the nanoparticle within the tumor, followed by the subsequent release of a potent anti-tumor drug.

The study results were compelling, demonstrating:

• Through concentrating and trapping the two drugs in the tumor, the nanocapsule dramatically inhibited tumor growth in mice and extended survival time compared to other drugs and drug combinations.
• Greater efficacy was observed when both drugs were delivered within the nanocapsule compared to the individual drugs administered in combination, illustrating the advantage of using the nanocapsule to deliver combinations of drugs.
• In addition, data on white blood cell counts showed that the nanocapsule format also provides a safety advantage compared to positive controls.
• Finally, data in the Nature paper demonstrated that the unique format of the nanocapsule has the potential to overcome resistance mechanisms of cancer.